Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China

International Journal of Epidemiology

Volumn 33, Issue 1, 2004, Pages 182-188

  Garten, Rebecca J ^a   Lai, Shenghan ^a   Zhang, Jinbing ^a   Liu, Wei ^b   Chen, Jie ^b   Vlahov, David ^c   Yu, Xiao Fang ^a  

^a JHBSPH   (United States)

^b Guangxi Center for HIV/AIDS Prevention and Control   (China)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

Author keywords

China; Epidemiology; Hepatitis C; Heroin; Injection drug use; Logistic model; Prevalence; Prevention; Risk factors; Substance abuse

Indexed keywords

DIAMORPHINE; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

DISEASE SPREAD; DISEASE TRANSMISSION; DRUG USER; HEPATITIS; YOUNG POPULATION;

ADULT; AGE; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK; RISK FACTOR; SELF REPORT; SEROCONVERSION; VIRUS TRANSMISSION;

ADULT; CHINA; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEROIN DEPENDENCE; HIV INFECTIONS; HIV SEROPREVALENCE; HIV-1; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; NEEDLE SHARING; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

ASIA; CHINA; EURASIA; FAR EAST;

EID: 3242814248     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyh019     Document Type: Article

References (32)

1. World Health Organization. Hepatitis C: Global Prevalence. Wkly Epidemiol Rec 1997;72:341-44.
2. Thorpe LE, Ouellet LJ, Hershow R et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155:645-53.
3. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
4. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl.1):S11-19.
5. Hahn JA, Page-Shafer K, Lunt PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001;34:180-87.
6. Diaz T, Des Jarlais DC, Vlahov D et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001;91:23-30.
7. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997;35:3274-77.
8. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999;149:203-13.
9. Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737-42.
10. Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis 1996;28:27-29.
11. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997;167:17-20.
12. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000;182:1588-94.
13. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91:42-46.
14. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 2000;75:19.
15. McCoy CB, McCoy HV, Lai S, Yu Z, Wang X, Meng J. Reawakening the dragon: changing patterns of opiate use in Asia, with particular emphasis on China's Yunnan province. Subst Use Misuse 2001;36:49-69.
16. Yu XF, Chen J, Shan Y et al. Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. J Acquir Immune Defic Syndr 1999;22:180-88.
17. Lai S, Chen J, Celentano D et al. Adoption of injection practices in heroin users in Guangxi Province, China. J Psychoactive Drugs 2000;32:285-92.
18. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl.1):S6-10.
19. Vlahov D, Anthony JC, Munoz A et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991;109:75-100.
20. Lai S, Liu W, Chen J et al. Changes in HIV-1 incidence in heroin users in Guangxi Province, China. J Acquir Immune Defic Syndr 2001;26:365-70.
21. Clayton D, Hills M. Statistical Methods in Epidemiology. New York: Oxford Univeristy Press, 1993.
22. Samuels JF, Vlahov D, Anthony JC, Chaisson RE. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict 1992;87:417-28.
23. van den Hoek JA, van Haastrecht HJA, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of heaptitis C virus infection among drug users in Amsterdam. J Infectious Dis 1990;162:823-26.
24. Gyarmathy VA, Neaigus A, Milller M, Friedman SR, Des Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002;30:448-56.
25. Santana Rodriguez OE, Male Gil ML, Hernadez Santana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serological markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 1998;14:555-61.
26. Quaglio G, Lugoboni F, Pajusco B et al. Factors associated with Hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis 2003;37:33-40.
27. van Ameijden EJ, van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993;9:255-62.
28. Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives. J Gastroenterol Hepatol 2000;15(Suppl.):E91-96.
29. Marincovich B, Castilla J, del Romero J et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003;79:160-62.
30. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002;36(Suppl.1):S99-105.
31. Tao QM, Wang Y, Wang H et al. Seroepidemiology of HCV and HBV infection in northern China. Gastroenterol Jpn 1991;26(Suppl.3): 156-58.
32. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: a case-control study. Drug Alcohol Depend 2002;66:189-98.